Psychedelic Stocks

Study Suggests Psychedelics Combat Anxiety by Exciting Cells in Hippocampus

Numerous studies have found that psychedelics hold the potential to treat mental-health conditions, including anxiety, depression and post-traumatic stress disorder. Now new research has found that psychedelics activate cells in the brain that help reduce anxiety.

The research was conducted by a global team of investigators, including at the Tata Institute of Fundamental Research and Cornell University. The researchers’ focus was on determining what types of cells and areas in the brain were involved when anxiety was suppressed using psychedelics. Associate professor Alex Kwan, the study’s senior author, explained that knowing the neurobiology involved would assist in the development of better medications.

For their research, the investigators used DOI (2,5-dimethoxy-4-iodoamphetamine), a psychedelic that’s similar to psilocybin and LSD. They used rats and mice for their experiments, which began by placing the rodents in a maze that had two sides: an exposed section above the ground and an enclosed area with walls.

The maze was designed to determine how anxious the rodents would be and how much they would explore. Investigators evaluated levels of anxiety based on time the animals spent in each area, observing that the animals spent most of their time in the closed wing. The scientists then administered the psychedelic into the bloodstream of the rodents and ran them through the maze. Once this was done, they infused the psychedelic into different regions in the brains of these rodents, and then observed any changes in their levels of anxiety.

The investigators found that the ventral hippocampus was the only region that could hold on to the psychedelic’s effect of decreasing anxiety. This research is based on prior studies that observed abnormal hyperactivity in the ventral hippocampus when animals are anxious.

Study’s coauthor assistant professor Antonio Fernandez-Ruiz also measured the electrical recordings of the brain. This helped identify interneurons that demonstrated increased firing following the psychedelic’s introduction. The study’s corresponding author, professor Vidita Vaidya, explained that the research offered a better understanding of cellular triggers for anxiety relief induced by psychedelics.

The investigators are now studying if the amygdala plays a role in this.

The research was supported by India’s Department of Atomic Energy, a Whitehall Research Grant, the Sree Padmavathi Venkateswara Foundation, the National Science Foundation, a Sackler Institute Award, a Klingenstein-Simons Fellowship, a Sloan Fellowship and the National Institutes of Health.

Other coauthors included scientists from the New York State Psychiatric Institute, Columbia University and Yale University. The research’s findings were reported in the “Neuron” journal.

The findings of this study can help to explain why startups such as Seelos Therapeutics Inc. (NASDAQ: SEEL) are focusing their R&D programs on developing psychedelic treatments targeting mental-health indications.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

4 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago